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ERYTHROPOIETINDOPING AS CAUSE OF SUDDEN DEATH
IN ATHLETES - AN EXPERIMENTAL STUDY
Abstract: Aims: To evaluare rhe cardiovascular (CV) effecrsof rhEPO rrearmenr in rars under
chronic aerobic exercise and ro assess rhe probable cause of sudden dearh in one raro
Protocol:Male Wisrar rars: conrrol - sedenrary;rhEPO - 50 IU/Kg/3xwk;swimming
(EX)- lhr, 3x/wk; EX+EPO. Haemarology, carecholamines and seroronin, redox srarus
and inflammarion, were assessed. One rar of EX+EPO group suffered a sudden dearh
episode.
Results: rhEPO rrearmenr in rrained rars promored several markers of increased CV risk.
The sudden dearh rar rissues presenred: lungs wirhour signs of drowning; brain wirh
vascular congesrion; LV hyperrrpphy and deregularion of cardiac fibers, rogerher wirh
a "cardiac liver", suggesring rhe hyporhesis of hearr failure as cause of dearh.
Conclusion: The sudden dearh of a EX+EPO rar, due ro a cardiac episode, rogerher
wirh rhe increased CV risk profile, srrongly suggesr a high life risk associared ro rhe
conrinuous rhEPO doping. The anaromo-parhological srudies were dererminanr ro
esrablish rhe cause of dearh.
Keywords: rhEPO; doping; chronic aerobic exercise; sudden dearh.
Introduction
Eryrhropoierin (EPO) is a glycoprorein hormone synthesized predominandy in rhe
kidneys which srimulares proliferarion and marurarion of eryrhroid cells in rhe bone
marrow (1). The increase in circularing RBC may be used ro increase 02 delivery ro
muscles, improving performance in sport (2). The availability of recombinant human
EPO (rhEPO) allowed irs use in doping. Sports aurhoriries prohibired rhe use of rhEPO
in 1988. The idea was, firsr, ro limir borh rhe degree of health risk and, second, rhe
degree of performance enhancement. The abusive use of rhEPO promores an increment
of BP, which, rogerher wirh rhe increase of Hcr and blood viscosity, strengrhens rhe
probabiliry of cardio/cerebrovascular events (3).
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In the early 1990s, there was a considerable speculation aboUt the involvement of
rhEPO doping in the death of professional cyclists (4,5). The artificial increase in RBC
and Hct, further enhanced by dehydratation during prolonged exercise, predisposes
to thromboembolic complications, which might be connected to sudden death in
sport practice (6). However, the cellular/molecular mechanisms underlying the sudden
death episodes are poorly clarified, as well as whether rhEPO use was linked to this
ourrageous phenomenon.
This study intended to evaluate the CV effects of rhEPO treatment on rats under




Male Wistar rats (Charles River Lab., Spain), 220-250g, were maintained in
appropriate conditioned: 22-24°C; 60% humidity; 12-h dark-light cycles; standard
rat chow (A04, Panlab, Letica, Spain) and water ad libitum.
After a period of adaptation of 2 wks, 4 groups (n=8) were tested for 10 wks-
treatment: control- sedentary (SED); rhEPO - 50 IU/Kg/3x1wk beta-EPO Recormon@,
Roche Pharm. (EPO); Exercised (EX) - swimming (1 hr, 3x/wk); EX+EPO. The
swimming rats were submitted to a 1 wk period of adaptation for minimizing the
water stress (bath set at 35:!:1°C). Sessions started with 15 min, increased 5 min/day
until a 60 min continuous period was achieved. Excepting 1 animal of the EX+EPO
group, which suffered a sudden death episode during an exercise session (wk 8), all
the animaIs have completed the 10-week protocol. Body weight (BW) was monitored,
and blood pressure (BP) and heart rate (HR) measured.
Samplecollectionand preparation
Serum samples were obtained from blood collected with i.p. ketamine anesthesia
at the end of treatments. The heart weights (HW) were measured in order to be used
as rrophy index (HW/BW). The following tissues were removed from the sudden
death rat: lungs, kidneys, brain, heart/left ventricle (LV) and liver and analyzed for
histomorphology (H&E staining).
Haematological data and renal function
Red blood cell (RBC) count, Hct and haemoglobin (Hb) were assessed by using an
automatic Coulter Counter@ (Beckman Coulter Inc., USA). Serum creatinine, ureia
and uric acid concentrations were assessed through an automatic Hitachi 717 analyser.
Catecholamine and serotonin
Plasma noradrenaline (NA), adrenaline (A), 5-hydroxy-tryptamine (5-HT) and
5-hydroxy-indoleacetic acid (5-HIAA) concentrations were evaluated by HPLC-ED (7).
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Redoxstatus
The thiobarbituric acid reactive-species (TBARs) assay was used to assess serum
products of lipid peroxidation, via malondialdehyde (MDA), according tO previously
described (7). Serum 3-nitrotyrosine (3-NT), which is an index of peroxynitrite
formation, was measured through an enzymatic immunoassay (HyCult-biotec.,
Netherlands). Serum total amioxidam status (TAS) was assessed via the ferric reducing
antioxidam potemial (FRAP) assay (7).
lnflammatory profile
Serum levels of interleukin 2 (IL-2), IL-1 r3, transforming growth factor r31
(TGF-r31), tumour necrosis factor a (TNF-a) and C-reactive protein (CRP) were
measured by Elisa kits (R&D Systems, USA).
Data analysis
Results are means :I:s.e.m. Comparisons betWeen groups were performed using
one-way ANOVA and Fisher's testo Significance was accepted at p less than 0.05.
Resul ts
Haematological data and renal function
EX+EPO rats presemed a significam (8.23:1:0.14, p<0.05) increase in RBC coum vs
the EX group (7.59:1:0.15). HaematOcrit and Hb showed a trend to idemical variation.
Exercised rats presemed significantly lower values of serum urea 07.35:1:0.26, p<0.05)
and uric acid (0.40:1:0.06 mg/dL, p<O.01). This reduction was prevemed in the EX+EPO
rats 08.60:1:0.63 and 0.50:1:0.03, respectively).
Bloodpressure, HR and heart trophy
BPs were higher in the EPO group vs contro!. The same partem was found for the
EX group (SBP: 123.92:1:1.38, DBP: 108.33:1:1.34 and MBP: 113.25:1:0.99 mmHg;
p<0.05 and HR: 394.58:1:8.66 beats/min). The EX+EPO rats presented a funher
increased in BPs 036.67:1:1.08, 123.22:1:2.04 and 127.33:1:1.62, respectively; p<O.OO1)
and HR (418.44:1:6.57, p<0.05). HW and HW/BW were significantly higher in the
EPO group vs contro!. The EX+EPO rats presemed a funher incremem in HW
(1.40:1:0.03 g, p<O.01) and HW/BW (3.06:1:0.16 g/kg, p<0.05) vs EX group (1.23:1:0.03
and 2.65:1:0.10).
Catecholamine and serotoninergic measures
In the EX+EPO rats, the plasma NA (9.32:1:1.43 ng/ml, p<0.05) and AD (1.96:1:0.18,
p<0.05) were significantly higher when compared with EX (5.10:1:0.96 and 1.04:1:0.09).
Conceming the serotoninergic plasma measures, the EX+EPO rats presemed plasma
5-HT (30.07:t4.45 ng/ml, p>O.OOl) and 5-HIAA (25.07:t2.38, p<0.05) substamially
higher than those found in EX 01.08:1:0.65 and 18.00:1:2.94).
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Redoxstatus and inflammatory profile
The EX+EPO rats presented a pro-oxidant effect, with a trend to increased values
of serum MDA (0.34:1:0.01 pmoI/L), MDA/TAS (1.53:1:0.05) and 3-NT (42.26:1:6.90
nmol/L) vs EX (0.30:1:0.02, 1.27:1:0.09 and 37.96:1:7.31, respectively).
Concerning the serum inflammatory markers, in the EX+EPO group there was
significandy higher values ofTGF-[31 (375.7:1:23.5 pg/mL, p<0.05) and a trend to higher
values ofIL-2 (59.08:1:3.76 pg/mL) vs EX (317.8:1:15.1 and 51.48:1:4.11, respectively).
Histomorphological analysis o/ tissuesfrom the sudden death rat (Fig. 1 and Fig. 2)
The rat HW was 1.82 g and the HW/BW was 4.04, significandy hypertrophic vs
the EX (1.23:1:0.03 and 2.65:1:0.10, respectively), demonstrating the tremendous effort
of the heart to maintain its functions. The histomorphological studies provided the
following results: the kidneys (l B1: glomerular and 1B2: tubular) from the suddenly
death rat showed eosinophilia and congestion, when compared with control kidneys
(lA1 and A2); the lungs showed signs of blood congestion, alveolar hemorrhage and
anoxia, without markers of drowning (l B3), vs control (lA3); the brain presented
vascular congestion (2B 1) vs control (2A1); the liver showed centre-Iobular congestion
and signals of "cardiac-liver", probably due to the heart failure (2B2) vs the normal
partern of control (2A2); there was LVH and desregulation of cardiac fibers (2A3 vs
2B3), suggesting the hypothesis of heart failure as cause of death.
Discussion
Since rhEPO became available as an erthropoiesis-stimulating drug, its abusing
use by athletes of endurance aerobic sports has been speculated and studied (2,8-10).
ln endurance sports, such as long-distance running, cycling and skiing, performance
relies on an adequate 02-supply to the heart and skeletal muscle. Hence, the rate of
maximal 02-uptake is an important determinant of aerobic physical power. However,
athletes who abuse rhEPO seem to consider only the benefit to performance and
ignore the short and long-term side-effects. There is a suspicion that rhEPO-induced
erythrocytosis caused the death of about 20 world-class cyclists, although this was
never proven (4,5), probably due to the lack of methodological capacity to distinguish
between the endogenous and the recombinant EPO as well as due the lack of knowledge
concerning the mechanisms underlying the side-effects. When Lasne and de Ceaurriz
(l1) were able tO distinguish the endogenous and the rhEPO in human urine, the
scandal of rhEPO use in sports was revealed, and the scientificlmedical community
was able to alert for the high health risks for the athletes.
The main risks of erythrocytosis (Hct>0.55 llI) include hypertension (HT), heart
failure, myocardial infarction and thromboembolic events. Endurance athletes are at
increased risk during the competition, if their blood viscosity increases further due to
the great loss of fluid associated with sweating (4,5,9,12). lnterestingly, some deaths
allegedly caused by rhEPO have not occurred during exercise but during periods of
physical inactivity, suggesting that the deleterious effects are prolonged.
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In our study, the rats under chronic exercise practice and rhEPO treatment showed
several markers of increased CVlthromboembolic risk. The increased RBC count, Hct
and Hb vs EX was confirmed, as expected. This was accompanied by development
of HT and tachycardia. Increased BP is a common feature in patients and athletes
under rhEPO treatment (8,9,13), and might result both from hyperviscosity and loss
of hypoxia-induced vasodilatation. rhEPO treatment was aiso able to promote heart
hypertrophy, which might be due to the blood hyperviscosity and could be viewed as
a need to ensure proper blood circulation to peripheral tissues. Increased tachycardia
might be explained by the increment in sympathetic activity, revealed by the increment
in plasma NA and AO. This effect of rhEPO was previously documented, namely on
hemodialyzed patients under rhEPO therapy (14). Furthermore, there was an increment
in plasma 5-HT, which might result from platelet overactivation, thus releasing the
granule contents. The increased platelet reactivity was reported by others (3), and is
in favour of an increased BP and thromboembolic complications.
rhEPO has been successfully used in anaemic patients to correct their anaemia.
However, its effects on non-hematopoietic cells and tissues, such as the brain and the
heart, suggested new important insights to its use in other pathological conditions,
such as the ischemia-reperfusion, heart failure and neurodegenerative diseases (15).
The rationale for its potential use in those disorders is based on its antioxidant, anti-
apoptotic and anti-inflammatory properties, already known as "pleiotropic actions"
(16). In our study, both the rhEPO treatment (per se) and the exercise practice have
demonstrated a beneficial effect on the redox status markers. However, rhEPO use
in rats under exercise favoured oxidative stress, given by the higher MOA/TAS index
and 3-NT content, which, considering the deleterious effect of ROS, represent an
increased risk. This partem was accompanied by a trend to higher values of IL-2 and
CRP, and a significant increment in TGF-j31. While the increase in the proliferation
marker TGF-j31 might eventually explain the heart hypertrophy, the increase in IL-2
and CRP suggest an inflammatory effect, further strengthening the deleterious actions
of rhEPO treatment in situations of regular exercise.
Ali the changes reported for the EX+rhEPO rats seem to be in agreement with
the sudden death episode occurred in one rat of the group, after 8 wks of protocol.
Actually, the rhEPO treatment in trained rats promoted an increase in RBC count
(contributing to hyperviscosity), HT, heart hypertrophy, sympathetic and serotonergic
overactivation, as well as oxidative stress and inflammation. The anatomo-pathological
tissue evaluation of a suddenly death rat, demonstrated that there were no drowning signs
in the lungs, despite some congestion marks. The kidneys showed some eosinophilia
and the brain revealed vascular congestiono Furthermore, and even more relevant,
there was some LVH and deregulation of cardiac fibers, together with a "cardiac liver",
suggesting the hypothesis of heart failure as the cause of death, which is in agreement
with the increased risk of cardio/cerebrovascular and thromboembolic events that the
functional studies in the EX+EPO aiso indicate.
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Conclusion
The sudden death of a rat belonging to the Ex+EPO group, due to a cardiac
episode, together with the increased CV risk profile, strongly suggest a high life risk
associated to the continuous rhEPO doping. The anatomo-pathological studies were
determinant to establish the cause of death.
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Figure 1 - Histomorphological H&E staining pictUres from the kidney glomerular (1) and tUbular
(2) regions and from the liver (3) from the control rats (A) when compared with those of the
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Figure2 - Hisromorphological H&E sraining picrures from rhe brain (1), rhe liver (2) and rhe
lefr venrricle (3) from rhe conrrol rars (A) when compared wirh rhose of rhe sudden dearh rar of
rhe EX+EPO group (B).
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